Effect of different doses of terofiban combined with ticagrelor on short-term cardiovascular events and platelet aggregation rate in patients with non-ST-elevation myocardial infarction

Sheng LU,Zai-xin YU,You-liang HUANG,Bi-feng TAN

DOI: https://doi.org/10.13191/j.chj.2017.0108

2017-01-01

Abstract:AIM To investigate the effect of different doses of terofiban combined with ticagrelor on short-term cardiovascular events and platelet aggregation rate in patients with (NSTEMI).METHODS One hundred and twenty-eight NSTEMI patients in our hospital were included in the study.According to different treatment methods,the patients were divided into ticagrelor group (group A,n =39),the conventional dose of tirofiban combined with ticagrelor group (group B,n =46) and small dose of tirofiban combined with Grillo group (group C,n =41).After 4 weeks of treatment,the platelet aggregation rate,fibrinogen (Fib) level and cardiovascular events,and incidence of adverse events were compared between the three groups.RESULTS After 4 weeks of treatment,the occurrence rate of composite endpoint in group A was significantly higher than those in group B and group C (P ＜ 0.05).The platelet aggregation rate and blood Fib levels in group B and group C were significantly lower than those in group A (P ＜ 0.05).The incidence of adverse reactions in group B was significantly higher than those in group A and group C (P ＜ 0.05).CONCLUSION Conventional dose and small dose of tirofiban combined with ticagrelor can reduce short-term cardiovascular events in NSTEMI patients and enhance the inhibition of platelet aggregation.Small dose of tirofiban reduces the incidence of adverse reactions.